508
Participants
Start Date
October 17, 2013
Primary Completion Date
May 4, 2015
Study Completion Date
November 12, 2015
MK-1293
MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Lantus™
Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
Prandial Insulin
Participants will continue their prandial insulin during the study.
Merck Sharp & Dohme LLC
INDUSTRY